Alembic Ltd
ALEMBICLTDAlembic Ltd is cheap for a reason. The P/BV sits at the 33rd percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: the P/BV sits at the 33rd percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn.
The price is in a downtrend (48 weeks in) while the P/BV sits at the 33rd percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −1.5% year on year, with the the net margin at 111.7%. What settles it: whether the quarters turn before the discount closes.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Alembic Ltd trades at ₹91.1, in a downtrend and 48 weeks into that stage. That is −2.5% against its own 200-day average. It sits at 51% of a 52-week range of ₹75 to ₹107. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 48 of stage 4, confirmed. At ₹91.1 it trades −2.5% versus its 200-day average and sits at 51% of its 52-week range (₹75–₹107).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +203% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each ₹1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
Alembic Ltd trades at 1.0× P/BV, near the bottom of its own range — cheaper only 33% of the time. Its long-run median P/BV is 1.0×, measured across 10.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 1.0× is near the bottom of its own range — cheaper only 33% of the time, against a long-run median of 1.0× measured over 10.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year book value grew while the price moved −18.1% — price and book moved together, holding the multiple in its range.
The price move, decomposed: over 5y, of the −5.5%/yr price move, ~+1.1%/yr came from book-value growth and ~−6.6 pp from the multiple (compressing); over 10y, of the +11.4%/yr price move, ~+11.4%/yr came from book-value growth and ~+0.0 pp from the multiple (roughly flat). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Alembic Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +79.7% at its peak to +8.1% but is still expanding. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.1% | +23.6% | +26.5% | +6.0% |
| Profit | +1.9% | +18.4% | −1.6% | +3.0% |
| EPS | +2.1% | +18.5% | −1.5% | +3.5% |
| Share price | −18.1% | +3.3% | −5.5% | +11.4% |
4-Factor Sector Score
52.8/100 — rank 7 of 18 in Finance - Holding Company · 78% evidence confidence
Alembic Ltd scores 52.8 out of 100 against the 18 companies it is compared with in Finance - Holding Company, ranking 7. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 11.8 + 18.1 + 16.7 + 6.2 = 52.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fee and other income.
Alembic Ltd reported ₹60.0 Cr of income in the Mar 26 quarter, +0.0% year on year. Over 10 years it has compounded at 6.0% a year. The last full year, FY26, came in at ₹240 Cr. The last four reported quarters add to ₹240 Cr.
FY26 revenue came in at ₹240 Cr (+8.1% on the year), capping 10 years at 6.0% compound. The latest quarter (Mar 26) printed ₹60.0 Cr, +0.0% year on year.
Pace check: the last four quarters averaged +7.8% growth against the decade's 6.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.1% over the last 4 quarters against +23.6%/yr over the last 8 — rolling over; TTM profit +2.3% vs +8.8%/yr — rolling over.
Net margin Net margin — what the bank keeps of every ₹100 of revenue after every cost, provision and tax. It is the cleanest single margin we can read for a lender.
Alembic Ltd's net margin is 111.7% in the Mar 26 quarter, −1.6 percentage points against the same quarter a year ago. Across 13 fiscal years the net margin has ranged 3.6% to 463.5%. The current quarter sits inside that band.
The latest quarter's net margin is 111.7%, −1.6 pp against the same quarter a year ago. Across 13 fiscal years the net margin has ranged 3.6%–463.5%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Alembic Ltd earned ₹67.0 Cr of net profit in the Mar 26 quarter, −1.5% year on year. Full-year FY26 profit was ₹317 Cr. The 10-year compound rate is 3.0%. That is 111.7% of the quarter's revenue. The same quarter a year earlier earned ₹68.0 Cr.
Mar 26 profit was ₹67.0 Cr, −1.5% year on year. On the full year, FY26 printed ₹317 Cr (+1.9%), and the 10-year compound rate is 3.0%.
🚨 Why profit moved: revenue contributed +0.0% and the margin −1.6 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +1.8% vs revenue +7.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for Alembic Ltd, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book grows, revenue grows with it. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
Alembic Ltd's revenue grew +8.1% in FY26 to ₹240 Cr, so the book is growing. The latest quarter ran +0.0% year on year. The net margin on that income is 111.7%, −1.6 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY26 revenue was ₹240 Cr, +8.1% on the year, and the latest quarter ran +0.0% year on year. The net margin on that revenue is 111.7% this quarter (−1.6 pp YoY) — growth with a narrowing margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — gross NPA is the loan-quality read we carry here.
Returns on equity and assets Two numbers usually rate a lender: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys.
A clean annual return-on-equity ladder is not held for Alembic Ltd. For an insurer especially the standard bank ratios are not the right lens, so this page does not force them onto the filings rather than estimating a series it cannot support. The revenue, margin and ownership sections above and below are the reads this page stands behind.
We do not hold a clean annual return-on-equity series for Alembic Ltd — for an insurer especially, the standard bank ratios are not the right lens, so this page does not force them. The revenue, margin and ownership sections above and below are the reads we stand behind.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Alembic Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 70.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.2 points over 8 quarters to 1.3%; Promoters: +0.0 points over 8 quarters to 70.9%; Domestic institutions: +0.0 points over 8 quarters to 0.1%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Alembic Ltd: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Jindal Poly Investment & Finance Company LtdJPOLYINVST | 79.8/100Favorable setup76% evidence | ASLEEP | 30.0/35 Income 100% · PAT 100% 71% evidence | 20.7/25 ROA 47.9% · ROE 54.8% · GNPA — 68% evidence | 14.5/20 P/BV 0.67× · P/BV÷ROE 0.01 100% evidence | 14.6/20 RS sector 32.3% · RS bench -2.4% · 1Y 28%0 of 10 weeks ahead 70% evidence |
| Exact sum: 30 + 20.7 + 14.5 + 14.6 = 79.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Kama Holdings LtdKAMAHOLD | 68.3/100Favorable setup78% evidence | ASLEEP | 24.3/35 Income 7.4% · PAT 47% 75% evidence | 17.8/25 ROA 7.3% · ROE 12.7% · GNPA — 72% evidence | 18.1/20 P/BV 1.01× · P/BV÷ROE 0.08 100% evidence | 8.1/20 RS sector -0.5% · RS bench -9.8% · 1Y -18.1%1 of 10 weeks ahead 70% evidence |
| Exact sum: 24.3 + 17.8 + 18.1 + 8.1 = 68.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3TVS Holdings LtdTVSHLTD | 65.3/100Favorable setup67% evidence | TURNING | 25.2/35 Income 31.7% · PAT 49.4% 52% evidence | 16.2/25 ROA — · ROE 30.6% · GNPA — 34% evidence | 10.3/20 P/BV 4.6× · P/BV÷ROE 0.15 100% evidence | 13.6/20 RS sector 4.5% · RS bench 3.8% · 1Y 22.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.2 + 16.2 + 10.3 + 13.6 = 65.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Godrej Industries LtdGODREJIND | 59.5/100Mixed-positive evidence73% evidence | LEADER | 20.8/35 Income 13.1% · PAT 29.8% 45% evidence | 14.1/25 ROA 1.9% · ROE 9.3% · GNPA — 68% evidence | 5.1/20 P/BV 3.97× · P/BV÷ROE 0.43 100% evidence | 19.5/20 RS sector 22% · RS bench 20.7% · 1Y 16%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 14.1 + 5.1 + 19.5 = 59.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Cholamandalam Financial Holdings LtdCHOLAHLDNG | 56.8/100Mixed-positive evidence76% evidence | ASLEEP | 19.0/35 Income 17.9% · PAT 15.7% 55% evidence | 18.0/25 ROA 2.2% · ROE 17.5% · GNPA — 68% evidence | 15.2/20 P/BV 1.86× · P/BV÷ROE 0.11 100% evidence | 4.6/20 RS sector -10.9% · RS bench -12.1% · 1Y -23%3 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 18 + 15.2 + 4.6 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Bajaj Finserv LtdBAJAJFINSV | 54.4/100Mixed-positive evidence61% evidence | TURNING | 18.2/35 Income 14.5% · PAT 10.5% 52% evidence | 14.8/25 ROA — · ROE 13.2% · GNPA — 34% evidence | 8.0/20 P/BV 4.17× · P/BV÷ROE 0.32 100% evidence | 13.4/20 RS sector 2.1% · RS bench 3.8% · 1Y 2.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 14.8 + 8 + 13.4 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Alembic Ltdthis pageALEMBICLTD | 52.8/100Mixed-positive evidence78% evidence | ASLEEP | 11.8/35 Income 8.1% · PAT 2.3% 75% evidence | 18.1/25 ROA 12.2% · ROE 13% · GNPA — 72% evidence | 16.7/20 P/BV 0.96× · P/BV÷ROE 0.07 100% evidence | 6.2/20 RS sector -10.9% · RS bench -5.3% · 1Y -20.8%1 of 10 weeks ahead 70% evidence |
| Exact sum: 11.8 + 18.1 + 16.7 + 6.2 = 52.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Bajaj Holdings & Investment LtdBAJAJHLDNG | 52.3/100Mixed-positive evidence61% evidence | TURNING | 18.1/35 Income 30.3% · PAT 5.6% 52% evidence | 13.8/25 ROA — · ROE 11.9% · GNPA — 34% evidence | 12.3/20 P/BV 1.73× · P/BV÷ROE 0.14 100% evidence | 8.1/20 RS sector -9.6% · RS bench -0.7% · 1Y -18.1%1 of 11 weeks ahead 70% evidence |
| Exact sum: 18.1 + 13.8 + 12.3 + 8.1 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Tata Investment Corporation LtdTATAINVEST | 49.3/100Mixed-negative evidence78% evidence | ASLEEP | 25.3/35 Income 30.6% · PAT 38.3% 75% evidence | 11.2/25 ROA 1.3% · ROE 1.4% · GNPA — 72% evidence | 3.9/20 P/BV 1.17× · P/BV÷ROE 0.81 100% evidence | 8.9/20 RS sector -1.1% · RS bench -4.8% · 1Y 2.6%2 of 10 weeks ahead 70% evidence |
| Exact sum: 25.3 + 11.2 + 3.9 + 8.9 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Maharashtra Scooters LtdMAHSCOOTER | 44.8/100Mixed-negative evidence61% evidence | TURNING | 21.9/35 Income 41% · PAT 15.3% 52% evidence | 10.8/25 ROA — · ROE 1.1% · GNPA — 34% evidence | 3.1/20 P/BV 0.54× · P/BV÷ROE 0.51 100% evidence | 9.0/20 RS sector -0.4% · RS bench -8.4% · 1Y -11%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.9 + 10.8 + 3.1 + 9 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Rane Holdings LtdRANEHOLDIN | 44.6/100Mixed-negative evidence67% evidence | TURNING | 16.6/35 Income 34.9% · PAT -38.5% 45% evidence | 13.9/25 ROA 4% · ROE 7% · GNPA — 68% evidence | 5.1/20 P/BV 2.16× · P/BV÷ROE 0.31 100% evidence | 9.0/20 RS sector -10.9% · RS bench 22.4% · 1Y 11.6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 13.9 + 5.1 + 9 = 44.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Max India LtdMAXIND | 40.9/100Thin evidence · provisional55% evidence | TURNING | 23.5/35 Income 30.8% · PAT 13.5% 45% evidence | 4.0/25 ROA -18.2% · ROE -32.8% · GNPA — 68% evidence | 8.3/20 P/BV 2.21× · P/BV÷ROE — 40% evidence | 5.1/20 RS sector -16.6% · RS bench -5.2% · 1Y -22.8%5 of 10 weeks ahead 70% evidence |
| Exact sum: 23.5 + 4 + 8.3 + 5.1 = 40.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Vardhman Holdings LtdVHL | 39.8/100Mixed-negative evidence76% evidence | ASLEEP | 7.4/35 Income -47.8% · PAT -15.9% 71% evidence | 14.8/25 ROA 5.8% · ROE 5.9% · GNPA — 68% evidence | 8.0/20 P/BV 0.29× · P/BV÷ROE 0.05 100% evidence | 9.6/20 RS sector -0.3% · RS bench -6.1% · 1Y -17.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 7.4 + 14.8 + 8 + 9.6 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Elcid Investments LtdELCIDIN | 36.3/100Mixed-negative evidence69% evidence | ASLEEP | 14.8/35 Income -36.8% · PAT -28.3% 48% evidence | 9.7/25 ROA 1.3% · ROE 1.2% · GNPA — 72% evidence | 8.6/20 P/BV 0.26× · P/BV÷ROE 0.21 70% evidence | 3.2/20 RS sector -8.7% · RS bench -9.7% · 1Y -17.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 9.7 + 8.6 + 3.2 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Kalyani Investment Company LtdKICL | 34.1/100Adverse evidence72% evidence | TURNING | 8.0/35 Income 1.3% · PAT -47.9% 75% evidence | 6.3/25 ROA 0.3% · ROE 0.4% · GNPA — 72% evidence | 5.0/20 P/BV 0.21× · P/BV÷ROE 0.57 70% evidence | 14.8/20 RS sector 3.7% · RS bench 8.8% · 1Y 11.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 8 + 6.3 + 5 + 14.8 = 34.1 · Decision use: Price leads the evidence: RS versus the benchmark is 8.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Max Financial Services LtdMFSL | 29.0/100Adverse evidence78% evidence | ASLEEP | 9.6/35 Income 2.6% · PAT -74% 75% evidence | 6.7/25 ROA 0.1% · ROE 1.5% · GNPA — 72% evidence | 0.4/20 P/BV 9.8× · P/BV÷ROE 6.45 100% evidence | 12.3/20 RS sector 19.3% · RS bench -9.5% · 1Y -1.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.6 + 6.7 + 0.4 + 12.3 = 29 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17JSW Holdings LtdJSWHL | 26.0/100Adverse evidence78% evidence | ASLEEP | 9.8/35 Income -27.1% · PAT -25.4% 75% evidence | 7.8/25 ROA 0.4% · ROE 0.5% · GNPA — 72% evidence | 4.4/20 P/BV 0.38× · P/BV÷ROE 0.83 70% evidence | 4.0/20 RS sector -29.1% · RS bench -29.9% · 1Y -46.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 7.8 + 4.4 + 4 = 26 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Pilani Investment & Industries Corporation LtdPILANIINVS | 23.1/100Adverse evidence69% evidence | ASLEEP | 12.0/35 Income -6.4% · PAT -68.5% 48% evidence | 5.3/25 ROA 0.2% · ROE 0.2% · GNPA — 72% evidence | 4.1/20 P/BV 0.3× · P/BV÷ROE 1.5 70% evidence | 1.7/20 RS sector -11.5% · RS bench -12.4% · 1Y -15.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 5.3 + 4.1 + 1.7 = 23.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Alembic Ltd's share price today?
Alembic Ltd trades at ₹91.1, −18.1% over the past year. The company is valued at ₹2,340 Cr. The stock sits at 51% of its 52-week range of ₹75–₹107, −2.5% versus its 200-day average. On the tape, the price is in a downtrend, 48 weeks in. — as of 31 July 2026.
What were Alembic Ltd's latest quarterly results?
Alembic Ltd reported total income of ₹60.0 Cr and net profit of ₹67.0 Cr for the Mar 26 quarter. Income rose 0.0% and profit fell 1.5% year on year. Earnings per share were ₹2.61. The net margin was 111.7%, 1.6 pp lower than a year earlier. — as of 31 July 2026.
What is Alembic Ltd's revenue?
Alembic Ltd reported revenue of ₹60.0 Cr in the Mar 26 quarter, +0.0% year on year. For the full FY26 fiscal year, revenue was ₹240 Cr (+8.1%). Over the last 10 years revenue compounded at 6.0% a year. — as of 31 July 2026.
What is Alembic Ltd's profit?
Alembic Ltd earned ₹67.0 Cr of net profit in the Mar 26 quarter, −1.5% year on year. Full-year FY26 profit was ₹317 Cr. The net margin ran 111.7% in the latest quarter. — as of 31 July 2026.
What is Alembic Ltd's market cap?
Alembic Ltd's market capitalisation is ₹2,340 Cr at a share price of ₹91.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Alembic Ltd's P/BV ratio?
Alembic Ltd trades at a P/BV of 1.0×, at the 33rd percentile of its own 10-year range, against a long-run median of 1.0×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Alembic Ltd pay a dividend?
Yes — Alembic Ltd's dividend payout was 19% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Alembic Ltd overvalued?
On its own history, Alembic Ltd looks cheap against its own history: its P/BV of 1.0× has been cheaper only 33% of the time in 10 years (long-run median 1.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Alembic Ltd growing?
Not right now — Alembic Ltd's latest numbers are shrinking: latest-quarter revenue +0.0% year on year, profit −1.5%, and the the net margin −1.6 pp at 111.7%. The 10-year compound rates are 6.0% (revenue) and 3.0% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Alembic Ltd performing?
Alembic Ltd is in a downtrend, 48 weeks in. Its latest quarter's income rose 0.0% and profit fell 1.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Alembic Ltd in?
Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +79.7% at its peak to +8.1% but is still expanding. The read comes from the last 12 quarters of growth (revenue growth +8.1% latest, profit growth +2.3% latest, eps growth +2.1% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Alembic Ltd in an uptrend?
No — the price is in a downtrend (week 48 of stage 4), trading −2.5% versus its 200-day average and at 51% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Alembic Ltd beating the market?
On recent form, yes — Alembic Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +203% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Alembic Ltd's share price go up?
This page publishes no price forecast for Alembic Ltd. What it measures instead: the share price is ₹91.1, the price is in a downtrend 48 weeks in. Its P/BV of 1.0× sits at the 33rd percentile of its own 10-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns Alembic Ltd?
Promoters hold 70.9% of Alembic Ltd, foreign institutions 1.3%, domestic institutions 0.1% and the public 27.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Is Alembic Ltd's loan book healthy?
We do not hold quarterly loan-book quality numbers for Alembic Ltd, so this page says that plainly. The cleanest available reads are revenue growth (+8.1% in FY26) and the net margin on it (111.7%) — as of 31 July 2026.
Where is Alembic Ltd in its business cycle?
Alembic Ltd's FY26 net margin was 132.1%, against a 13-year band of 3.6%–463.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 111.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Alembic Ltd story?
The sharpest disagreement: the P/BV sits at the 33rd percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Alembic Ltd a stock worth studying right now?
This is not investment advice. The machine read: Alembic Ltd is cheap for a reason. The P/BV sits at the 33rd percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the quarters turn before the discount closes. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.